Pulmatrix, Inc.Company Review & Valuation

PULM
Nasdaq
Latest Price
1.19USD
Market Capitalization
23.79mUSD

About Pulmatrix, Inc.

Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseasShow morees, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, including asthma and chronic obstructive pulmonary disease (COPD). The company is also involved in developing PUR0200, a reformulation of an existing long-acting antimuscarinic agent that has completed Phase Ib clinical development, which blocks the effects of acetylcholine on muscarinic receptors to reverse airway obstruction in COPD patients. It has a license agreement with RespiVert Ltd. to develop kinase inhibitor for access to a portfolio of novel drug candidates; and a partnership agreement with Vectura Group plc to develop its drug candidate. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.Show less

Industry
Biotechnology
HQ Location
Lexington, Massachusetts

Stock Price

Price data not available for Pulmatrix, Inc..

Performance

Please login or create a free account to view the contents of this section.

Similar Companies

Vertex Pharmaceuticals
Incyte
Regeneron Pharmaceuticals
Celgene

back to top